Explore

Trendline Trendline
TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase

TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase

TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase
Trendline Trendline
Parabilis Medicines Strengthens Board with Appointment of Finance Leader Alan M. Sebulsky

Parabilis Medicines Strengthens Board with Appointment of Finance Leader Alan M. Sebulsky

Parabilis Medicines Strengthens Board with Appointment of Finance Leader Alan M. Sebulsky
Trendline Trendline
Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials

Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials

Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials
Trendline Trendline
Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs
Trendline Trendline
Janux Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress

Janux Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress

Janux Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress
Trendline Trendline
Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast
Trendline Trendline
TORL BioTherapeutics Appoints Aran Maree as CEO to Drive Growth in Cancer Therapeutics

TORL BioTherapeutics Appoints Aran Maree as CEO to Drive Growth in Cancer Therapeutics

TORL BioTherapeutics Appoints Aran Maree as CEO to Drive Growth in Cancer Therapeutics
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform
Trendline Trendline
NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week
Trendline Trendline
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark